 | • レポートコード：TPM-DJ144 • 出版社/出版日：Transparency Market Research / 2019年3月11日 • レポート形態：英文、PDF、184ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、乾癬性関節炎治療薬の世界市場について調べ、乾癬性関節炎治療薬の市場規模、市場動向、市場シェア、市場環境、市場予測、関連企業情報などをまとめました。 |
Psoriatic Arthritis Therapeutics Market – Overview
This report by Transparency Market Research analyses the global psoriatic arthritis therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made, which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of psoriatic arthritis.
The global psoriatic arthritis therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global psoriatic arthritis therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global psoriatic arthritis therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global psoriatic arthritis therapeutics market.
The market overview section comprises impact factors such as key market dynamics, including drivers, restraints, and opportunities, affecting the global psoriatic arthritis therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global psoriatic arthritis therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the industry, epidemiology analysis of the psoriatic arthritis, product portfolio overview of leading players, and market attractiveness analysis in the global psoriatic arthritis therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.
Scope
The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Based on route of administration, the global market has been segregated into oral, parenteral, and topical. In terms of distribution channel, the global psoriatic arthritis therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section.
The report provides a detailed outline/blueprint of the global psoriatic arthritis therapeutics market, which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players.
Competitive landscape
Major players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.
The global psoriatic arthritis therapeutics market has been segmented into:
Global Psoriatic Arthritis Therapeutics Market, by Drug Class
TNF Inhibitors
Interleukin Inhibitors
PDE4 Inhibitors
Others
Global Psoriatic Arthritis Therapeutics Market, by Route of Administration
Oral
Parenteral
Topical
Global Psoriatic Arthritis Therapeutics Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Psoriatic Arthritis Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Psoriatic Arthritis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, 2016–2026
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
5.3. Disease Prevalence & Incidence Rate globally with key Countries
6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
6.3.1. TNF Inhibitors
6.3.2. Interleukin Inhibitors
6.3.3. PDE4 Inhibitors
6.3.4. Others
6.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class
7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration , 2016–2026
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration
8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel
9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Psoriatic Arthritis Therapeutics Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Region
10. North America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
10.2.1. TNF Inhibitors
10.2.2. Interleukin Inhibitors
10.2.3. PDE4 Inhibitors
10.2.4. Others
10.3. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Psoriatic Arthritis Therapeutics Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Psoriatic Arthritis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
11.2.1. TNF Inhibitors
11.2.2. Interleukin Inhibitors
11.2.3. PDE4 Inhibitors
11.2.4. Others
11.3. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
12.2.1. TNF Inhibitors
12.2.2. Interleukin Inhibitors
12.2.3. PDE4 Inhibitors
12.2.4. Others
12.3. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Psoriatic Arthritis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast by Drug Class, 2016–2026
13.2.1. TNF Inhibitors
13.2.2. Interleukin Inhibitors
13.2.3. PDE4 Inhibitors
13.2.4. Others
13.3. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Drug Class, 2016–2026
14.2.1. TNF Inhibitors
14.2.2. Interleukin Inhibitors
14.2.3. PDE4 Inhibitors
14.2.4. Others
14.3. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Route of Administration, 2016–2026
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by Tier and Size of companies)
15.2. Global Psoriatic Arthritis Therapeutics Market Share Analysis by Company (2017)
15.3. Company Profiles
15.3.1. AbbVie, Inc.
15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)
15.3.3. Novartis AG
15.3.4. Amgen, Inc.
15.3.5. CELGENE CORPORATION
15.3.6. Pfizer, Inc.
15.3.7. Eli Lilly and Company
15.3.8. UCB Inc.
15.3.9. Biogen Inc.
15.3.10. Bristol-Myers Squibb Company
Table 01: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 07: North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 08: North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 11: Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 12: Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 16: Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 20: Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026